Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atefeh Talebi

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Journal of Cardiac Failure|August 17, 2025
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trialDavid D Berg, Kieran Docherty, Atefeh Talebi, et al.
JAMA Cardiology|March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionKirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
European Heart Journal|August 26, 2022
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillationToru Kondo, Azmil H Abdul-Rahim, Atefeh Talebi, et al.
European Journal of Heart Failure|May 3, 2024
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fractionMingming Yang, Toru Kondo, Atefeh Talebi, et al.
European Journal of Heart Failure|May 14, 2024
Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HFJames P Curtain, Atefeh Talebi, Alasdair McIntosh, et al.
Journal of the American College of Cardiology|November 9, 2024
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFMingming Yang, Alasdair D Henderson, Atefeh Talebi, et al.
JAMA Cardiology|April 26, 2023
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER TrialPardeep S Jhund, Brian L Claggett, Atefeh Talebi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 16, 2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HFAlasdair D Henderson, Kieran F Docherty, Atefeh Talebi, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Journal of Cardiac Failure|August 17, 2025
Growth differentiation factor-15 and the effect of dapagliflozin in heart failure: insights from the DAPA-HF trialDavid D Berg, Kieran Docherty, Atefeh Talebi, et al.
JAMA Cardiology|March 27, 2024
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection FractionKirsty McDowell, Toru Kondo, Atefeh Talebi, et al.
European Heart Journal|August 26, 2022
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillationToru Kondo, Azmil H Abdul-Rahim, Atefeh Talebi, et al.
European Journal of Heart Failure|May 3, 2024
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fractionMingming Yang, Toru Kondo, Atefeh Talebi, et al.
European Journal of Heart Failure|May 14, 2024
Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HFJames P Curtain, Atefeh Talebi, Alasdair McIntosh, et al.
Journal of the American College of Cardiology|November 9, 2024
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFMingming Yang, Alasdair D Henderson, Atefeh Talebi, et al.
JAMA Cardiology|April 26, 2023
Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER TrialPardeep S Jhund, Brian L Claggett, Atefeh Talebi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 16, 2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HFAlasdair D Henderson, Kieran F Docherty, Atefeh Talebi, et al.
Pageof 7